


Claims

1. A crystal of the compound of the following formula:




wherein the crystal has two or more peaks in diffraction angles (2θ) selected from $8.6\pm 0.2^\circ$, $14.1\pm 0.2^\circ$, $17.4\pm 0.2^\circ$, $20.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $26.3\pm 0.2^\circ$, $29.6\pm 0.2^\circ$ and $35.4\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

2. The crystal according to claim 1, wherein the crystal has peaks in diffraction angles (2θ) of: $8.6\pm 0.2^\circ$, $14.1\pm 0.2^\circ$, $17.4\pm 0.2^\circ$, $20.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $26.3\pm 0.2^\circ$, $29.6\pm 0.2^\circ$ and $35.4\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

3. A pharmaceutical composition comprising the crystal according to claim 1 and a pharmaceutically acceptable carrier or diluent.

~~4. A crystal of the compound of the following formula:~~




~~wherein the crystal has two or more peaks in diffraction angles (2θ) selected from $4.4\pm 0.2^\circ$, $8.9\pm 0.2^\circ$, $11.7\pm 0.2^\circ$, $14.9\pm 0.2^\circ$, $22.3\pm 0.2^\circ$, $24.4\pm 0.2^\circ$, $28.0\pm 0.2^\circ$ and $31.5\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.~~

~~5. The crystal according to claim 4, wherein the crystal has peaks in diffraction angles (2 θ) of 4.4 $\pm$ 0.2 $^{\circ}$, 8.9 $\pm$ 0.2 $^{\circ}$, 11.7 $\pm$ 0.2 $^{\circ}$, 14.9 $\pm$ 0.2 $^{\circ}$, 22.3 $\pm$ 0.2 $^{\circ}$, 24.4 $\pm$ 0.2 $^{\circ}$, 28.0 $\pm$ 0.2 $^{\circ}$ and 31.5 $\pm$ 0.2 $^{\circ}$ in an X-ray powder diffraction spectrum.~~

~~6. A pharmaceutical composition comprising the crystal according to claim 4 and a pharmaceutically acceptable carrier or diluent.~~

~~7. A crystal of the compound of the following formula:~~



~~wherein the crystal has two or more peaks in diffraction angles (2 θ) selected from 4.4 $\pm$ 0.2 $^{\circ}$, 8.7 $\pm$ 0.2 $^{\circ}$, 10.6 $\pm$ 0.2 $^{\circ}$, 17.3 $\pm$ 0.2 $^{\circ}$, 17.5 $\pm$ 0.2 $^{\circ}$, 22.0 $\pm$ 0.2 $^{\circ}$, 24.0 $\pm$ 0.2 $^{\circ}$, 24.1 $\pm$ 0.2 $^{\circ}$ and 31.0 $\pm$ 0.2 $^{\circ}$ in an X-ray powder diffraction spectrum.~~

~~8. The crystal according to claim 7, wherein the crystal has peaks in diffraction angles (2 θ) of 4.4 $\pm$ 0.2 $^{\circ}$, 8.7 $\pm$ 0.2 $^{\circ}$, 10.6 $\pm$ 0.2 $^{\circ}$, 17.3 $\pm$ 0.2 $^{\circ}$, 17.5 $\pm$ 0.2 $^{\circ}$, 22.0 $\pm$ 0.2 $^{\circ}$, 24.0 $\pm$ 0.2 $^{\circ}$, 24.1 $\pm$ 0.2 $^{\circ}$ and 31.0 $\pm$ 0.2 $^{\circ}$ in an X-ray powder diffraction spectrum.~~

~~9. A pharmaceutical composition comprising the crystal according to claim 7 and a pharmaceutically acceptable carrier or diluent.~~